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Abstract 
Psychiatric disorders represent a frequent comorbidity in patients with epilepsy affecting quality of 
life, morbidity and mortality. Evidence-based data on the management of these conditions are 
limited but a number of recommendations are now available to guide clinical practice. The present 
paper reviews the pharmacological treatment of psychiatric problems in epilepsy with special 
attention to data coming from randomised controlled trials (RCTs), pharmacological interactions 
with AEDs and the issue of seizure worsening during treatment with psychotropic drugs. 
Epidemiologically or clinically relevant psychiatric conditions are discussed namely mood and anxiety 
disorders, psychoses and attention deficit hyperactivity disorder. 
 
 
 
 
Key words: epilepsy, depression, anxiety, psychosis, attention deficit hyperactivity disorder, 
interactions, antiepileptic drugs, antidepressant drugs, antipsychotic drugs, methylphenidate 
  
 
 
 
  
3 
 
  
1. Introduction 
Psychiatric disorders represent a frequently reported comorbidity in patients with epilepsy affecting 
both mortality and morbidity (1). Epidemiological data show a uniformly increased prevalence in 
epilepsy as compared to the general population (2) and, in some cases, this partially reflects the 
severity of the seizure disorder as prevalence rates are higher in subjects with refractory syndromes 
as compared to patients with well controlled epilepsies (3). However, the clinical scenario seems to 
be more complex than that with multiple variables involved such as psychosocial issues (4), adverse 
effects of antiepileptic drugs (AEDs) (5) or neurobiological factors directly related to the seizures or 
the epileptic disorder (6). Moreover, it is now established that patients with epilepsy may 
experience a number of behavioural changes or psychiatric symptoms around the ictus that should 
be differentiated from comorbid psychiatric conditions. Historically, such symptoms have been 
classified according to their temporal relationship to the occurrence of seizures for practical 
reasons (peri-ictal/para-ictal symptoms and interictal symptoms) (Table 1). In the past, a number 
of authors identified and described these symptoms. In particular, Gowers (7) and Jackson (8)  but 
also by Kraepelin (9)  and Bleuler (10) pointed out that, in untreated patients, epileptic seizures 
can be accompained by a number of psychiatric symptoms and behavioural changes. The 
differentiation between peri-ictal and interictal psychiatric symptoms has relevant implications in 
terms of prognosis and treatment as peri-ictal symptoms are due to the underlying seizure disorder 
and AEDs remains the main treatment. 
The present paper reviews the pharmacological treatment of interictal psychiatric conditions with 
special attention to data coming from randomised controlled trials (RCTs), pharmacological 
interactions with AEDs and the issue of seizure worsening during treatment with psychotropic drugs. 
Epidemiologically or clinically relevant psychiatric conditions are discussed namely mood and anxiety 
disorders, psychoses and attention deficit hyperactivity disorder. 
 
2. MOOD DISORDERS 
2.1 Evidence from RCT in epilepsy 
Data on treatment of depression in epilepsy is still limited and relies heavily on clinical experience. 
The only double-blind trial on antidepressants in epilepsy was published 30 years ago and compared 
nomifensine, amitriptyline and placebo (11). Since then, a number of open trials in small samples of 
unselected patients with different epilepsy types have been published: sertraline (12,13), citalopram 
(14–16), reboxetine (15), mirtazapine (15), and fluoxetine (13). One study is of particular interest 
because it is the only published paper involving children and adolescents with epilepsy and 
depression (13). All these antidepressants showed to be effective and well tolerated but due to the 
lack of controlled about the pharmacological treatment of depression in epilepsy, the Epilepsy 
Foundation (17) and the International League Against Epilepsy (18) published a number of 
recommendations to guide clinicians. In general terms, it is reasonable to follow internationally 
accepted guidelines for the treatment of mood disorders outside epilepsy, applying individual 
adjustments, in the individual patient, according to the epilepsy type and the concomitant AEDs (19).  
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In general terms, it is important to distinguish between the acute treatment of depression (aimed 
at remission and recovery) and the long term treatment (aimed at avoiding recurrence). It is also 
important to point out that the patient is in remission when all symptoms go away. If remission 
lasts for 6 to 12 months, the patient is then considered in recovery. Worsening before a remission or 
before a remission has turned into a recovery, it is called relapse while a new episode after complete 
recovery is defined recurrence. Epidemiological studies of depression show that up to 90% of 
patients respond to one treatment or a combination of therapeutic interventions and among these 
subjects about 50% recover within 6 months and up to 75% in 2 years (20). It is still unknown 
whether patients with epilepsy and depression have similar remission and recovery rates although it 
is reasonable to hypothesise so.  
2.2 Pharmacokinetic interactions between antiepileptic and antidepressant drugs 
Antidepressants are usually classified into older or classic agents, such as tricyclic antidepressants 
(TCAs) and monoamine oxidase inhibitors (MAOIs), and newer antidepressants, such as selective 
serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs) and 
other antidepressants with varying mechanisms of actions (21). A number of papers have reviewed 
pharmacokinetic interactions between antidepressant and antiepileptic drugs (22,23).  
2.2.1 The effect of AEDs on antidepressants 
Among first generation of AEDs, carbamazepine (CBZ), phenytoin (PHT) and barbiturates (PB) are 
powerful inducers of several drug-metabolizing enzymes including CYPs (CYP 1A2, 2A6, 2B6, 2C9, 
2C19, 3A4) and UGTs (1A1, 2B7, 2B15). Valproate (VPA) has been traditionally considered a broad 
spectrum enzyme inhibitor on the CYPs (2C9, 2C19 and 3A4) and UGTs (1A4 and 2B7) (23). As all 
these enzymes contribute to the metabolism of the majority of antidepressants, these AEDs may 
present pharmacokinetic interactions with antidepressants. 
As far as TCAs are concerned, their metabolism is quite complex with multiple enzymatic pathways 
involved. Demethylation is mainly catalysed by CYP2C19, and to a lesser extent CYP1A2, 2C9 and 
3A4, while hydroxylation is primarily catalysed by CYP2D6 (22,23). Regarding the potential clinical 
relevance of pharmacokinetic interactions with AEDs, a number of factors have to be considered: (i) 
nortriptyline and desipramine are the demethylated metabolites of amitriptyline and imipramine, 
respectively; (ii) TCAs have a large therapeutic window; (iii) CBZ in particular seems to affect also the 
protein binding leading to a significant increase in the free fraction (24). For all these reasons, it is 
unlikely that interactions between TCAs and first generation AED inducers are clinically relevant and 
dosage adjustments may be needed on an individual basis rather than in a systematic way. The same 
principles apply for VPA. VPA can inhibit several metabolic pathways involved in TCA metabolism but 
toxic levels have been reported only in some rare cases (25,26). Clinicians should therefore monitor 
patients and adjust dosages in individual cases rather than adopting systematic dose adjustments.  
Regarding SSRIs, first generation inducers (i.e. CBZ, PHT and PB) seem to reduce the plasma levels of 
the majority of them by at least 25% (23). Again, whether this is clinically relevant depends on the 
individual patient. Studies on VPA are limited but it seems that there are no clinically relevant 
pharmacokinetic interactions. 
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As far as other antidepressants are concerned, inducers like CBZ, PHT or barbiturates obviously 
reduce the plasma levels of mirtazapine, venlafaxine and bupropion (23). This seems to be 
particularly evident for bupropion with up to 90% reduction in AUC when CBZ was added to a stable 
regime of 150 mg (27). VPA has no effect on bupriopion metabolism but seems to slightly increase 
the plasma levels of the active metabolite of venlafaxine, O-desmethylvenlafaxine (28). 
Compared to first-generation AEDs, new compounds have a better pharmacokinetic profile with a 
low risk of interactions. Oxcarbazepine (OXC) and topiramate (TPM) may have weak inducing 
properties, especially at high doses. A single study documented a possible interaction between OXC 
and clomipramine (29) but systematic studies are lacking. 
2.2.2 The effect of antidepressants on AEDs 
Data on the effects of TCAs on AEDs metabolism are limited although it seems that none of them 
have clinically relevant effect on CYP enzymes. In the case of SSRIs, some of them are inhibitors of 
the CYP 2C9, especially fluoxetine and fluvoxamine (23), and this can obviously impact on PHT 
metabolism (30,31) and partially on VPA (32). Data on sertraline are contradictory as in vitro studies 
showed quite weak inhibition properties on CYP enzymes (33) but a few case reports documented 
increased serum levels for VPA (34) and lamotrigine (LTG) (35). However, a retrospective study 
aimed at investigating potential pharmacokinetic interactions between LTG and sertraline showed 
no clinically relevant changes in LTG levels (36). Paroxetine, citalopram, mirtazapine, venlafaxine and 
bupropion do not affect the metabolism of AEDs.  
2.3 Pharmacodynamic interactions between antiepileptic and antidepressant drugs 
Pharmacodynamic interactions are rarely systematically studied. In general terms, they can be 
divided into positive and negative. Positive interactions represent additive or synergistic treatment 
effects and this can be potentially postulated for depression, anxiety, pain and migraine prophylaxis, 
but evidence-based data are limited. For example, pregabalin (PGB) is currently licensed for the 
treatment of generalised anxiety disorder and a recent study suggested a synergistic effects 
between antidepressants and PGB (37). Evidence-based data on augmentation strategies in 
neuropathic pain or migraine are limited although it is reasonable to hypothesise that the combined 
AED-antidepressant treatment could be favourable. Pharmacodynamic interactions are often 
discussed in the context of side effects but it is important to emphasise that there are no systematic 
studies on this regard. It is obvious to speculate that antidepressant-AED combinations can be 
associated, in selected cases, with increased risk of sedation, weight gain or other side effects. The 
relative activity of the individual compound on different receptor groups is of great relevance in this 
context and different antidepressants can have a different spectrum of activity even if they belong 
to the same antidepressant group (Figure 1). For example, it is well known that the muscarinic 
block (especially M1 receptors) can be associated with dry mouth, paradoxical excessive 
perspiration, constipation, blurred vision, mydriasis, metallic taste, and urinary retention while 
orthostatic hypotension are due to the alpha receptor  blockade (especially alpha 1). Anti-
histaminergic compounds are associated with drowsiness, sedation, and weight gain while sexual 
dysfunction, loss of libido, impaired erection or ejaculation, and anorgasmia are due to 
overactivation of 5-HT2 receptors (24). Individual TCAs or SSRIs have different activity on these 
receptors being responsible for a different spectrum of side effects and, as a consequence, a 
different risk of negative pharmacodynamic interactions (Table2).  
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2.4 Effect of antidepressants on seizure threshold 
That antidepressants may lower the seizure threshold leading to seizure exacerbation has 
represented for a long time a major concern. However, this was based on a priori assumption rather 
than on clinical evidence. The story of the association between antidepressants and seizures goes 
back to the 1950s and 1960s when a number of case reports documented epileptic seizures in 
patients treated with TCAs, especially imipramine (38,39). Subsequently EEG studies showed also 
activation of the EEG and epileptic abnormalities with amitriptyline and imipramine (40,41). This 
data, despite not systematic and based just on a few specific agents, led to the general impression 
that all antidepressants were proconvulsants. In reality, the issue of drug-related seizures is quite 
complex and it is not only confined to psychotropic medications. In general terms, multiple factors 
have to be taken into account (Table 3) and, on the contrary, studies in animal models suggest that 
serotonin potentiation is anticonvulsant (42–44).  
Among all antidepressants, maprotiline, high dose of clomipramine and amitriptyline (>200mg) and 
high doses of bupropion immediate release formulation (>450 mg) seem to be more frequently 
associated with seizures than others (21) (Table 4). However, it is important to bear in mind that 
current knowledge on seizure prevalence during antidepressant drug treatment is based on 
psychiatric populations and it is still unknown whether this data can be transferred to patients with 
epilepsy and whether some epileptic syndromes are more at risk than others (45). This point is of 
great relevance if we consider the increased prevalence of seizures in patients with mood disorders 
(46,47). In fact, it is now clear from epidemiological studies that the relationship between epilepsy 
and depression is bidirectional, meaning that not only patients with epilepsy are at increased risk of 
depression but also patients with mood disorders are at increased risk of epileptic seizures (6). If we 
take into account such an increase risk, the reported prevalence of epileptic seizures during 
treatment with antidepressants in patients with mood disorders (48) is, for the majority of 
compounds, lower than the expected (Table 4). 
2.5 The use of lithium in epilepsy 
The use of lithium in epilepsy is very rarely considered as a number of antiepileptic drugs are also 
considered first line treatment in bipolar disorder (e.g. VPA). In case lithium is needed, interactions 
with some specific AEDs have to be considered. In fact, the concomitant prescription of lithium and 
CBZ is associated with increased lithium toxicity, especially thyroid toxicity (49),  as well as a severe 
hyponatraemia when lithium is discontinued (50). The concomitant prescription with VPA is 
associated with increased risk of tremor, sedation and weight gain (21) while TPM can reduce the 
clearance of lithium leading to toxic levels (51). For other AEDs, especially LTG, there are no specific 
concerns and the combination should be well tolerated.  
In terms of proconvulsant effect, this seems to be a concern only in the context of toxicity. The 
majority of labs consider a therapeutic level between 0.4 mmol/l and 0.8 mmol/l for the prophylactic 
treatment of mood episodes and between 0.6 mmol/l and 1.0 mmol/l for the acute treatment of 
mania. In the majority of cases, symptoms of toxicity starts for levels above 1.5 mmol/l but it is 
advisable to maintain always concentrations below 1.0 mmol/l. Seizures have been reported in the 
context of overdose with serum levels higher than 3 mmol/l, while within the therapeutic levels, the 
effect of lithium on seizure frequency in individuals with epilepsy is inconsistent (52). If lithium is 
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needed and indicated, vigilant monitoring of blood levels and careful clinical follow up are 
warranted. 
3. ANXIETY DISORDERS 
3.1 Evidence from RCT in epilepsy 
If the number of studies on the treatment of depression in epilepsy is very limited, there are no 
controlled studies at all about treatment of anxiety disorders in epilepsy. The Commission on 
Neuropsychiatry of the International League Against Epilepsy published a collection of papers about 
treatment strategies in adults with epilepsy and psychiatric disorders (19) and one paper was 
dedicated to the treatment of anxiety disorders (53). In general terms, it is reasonable to adopt 
therapeutic protocols recommended in patients with anxiety disorders  considering the specific 
needs of patients with epilepsy (Table 5). SSRIs and cognitive behavioural therapy (CBT) can be 
considered first line treatment in patients with epilepsy and panic disorder. PGB can be considered 
first choice  in patients with epilepsy and generalised anxiety disorder given the amount of clinical 
data. In social anxiety disorder and post-traumatic stress disorder, SSRIs can be considered first 
choice, in particular sertraline and paroxetine due to the low impact for interactions and the 
favourable tolerability. For obsessive compulsive disorder CBT is considered first line treatment. 
When drug treatment is needed, SSRIs, in particular sertraline, have to be preferred. 
Although it is reasonable to embrace standardized protocols of treatment developed for people with 
anxiety without epilepsy, it is also evident that psychiatric disorders of epilepsy present, more often 
not, with atypical features (54,55) that may require individualised approaches. For this reason, 
studies in patients with epilepsy are anyway urgently needed. 
4. PSYCHOSES 
4.1 Evidence from RCT in epilepsy 
Antipsychotic drugs can be divided into first-generation (FGAP) and second-generation (SGAP) 
compounds (Table 6).  SGAP have progressively replaced old compounds in developed countries due 
to favourable long term tolerability (e.g. reversible extrapyramidal symptoms and low rates of 
tardive dyskinesia). However, it is important to bear in mind that there is no clear evidence that one 
generation is more or less effective than the other. In the absence of specific treatment guideline, 
psychotic symptoms in the context of an interictal psychosis (IIP) should be treated in line with well-
established treatment protocols for primary schizophrenia and related psychoses (56). As already 
discussed for mood and anxiety disorders, the Commission on Neuropsychiatry of the International 
League Against Epilepsy published a collection of papers about treatment strategies in adults with 
epilepsy and psychiatric disorders (19) and one paper was dedicated to the treatment of psychoses 
(57). 
Psychotic symptoms in IIP can be difficult to manage for a variety of reasons that commonly include 
poor response to treatment, individual differences in tolerability to antipsychotic drugs, potential 
interactions with AEDs and effect on seizure threshold, the individual’s adherence to psychiatric 
treatment (57). In addition, it has to be considered that at least 50% of patients are partially or 
completely non-adherent to treatment (57,58) and approximately 15% of IIP episodes may remit 
with no antipsychotic treatment (59).  
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4.2 Pharmacokinetic interactions between antiepileptic and antipsychotic drugs 
4.2.1 The effect of AEDs on antipsychotics 
As already discussed for antidepressants, first generation AEDs which induce CYP enzyme activity are 
burdened by a number of interactions. CBZ reduces the plasma levels of all antipsychotics (60) and 
regarding SGAP this has been shown for aripiprazole, clozapine, olanzapine, paliperidone, 
quetiapine, risperidone and ziprasidone (61). This interaction is particularly evident for quetiapine 
which is mainly metabolised by the CYP 3A4. In fact, the introduction of CBZ can lead to 
undetectable serum concentrations of quetiapine even at dosages of 700 mg per day (62). 
Oxcarbazapine (OXC) is a keto-analog of CBZ but seems to be a modest CYP 3A4 inducer, for this 
reason pharmacokinetic interactions with antipsychotics are usually not clinically relevant.  
As far as all other AEDs are concerned, they do not seem to have a major impact on SGAP 
metabolism. Individual differences in treatment response have to be carefully considered especially 
for drugs like olanzapine and clozapine that have a complex metabolism with multiple enzymatic 
pathways involved. Although VPA is usually regarded as an inhibitor, there are no reports of 
increased antipsychotic drug serum levels when prescribed in combination. Conversely, VPA seems 
to mildly induce, in some selected cases, the metabolism of some SGAP (i.e. olanzapine, aripiprazole, 
clozapine, quetiapine) (61). These interactions are rarely clinically relevant and should be considered 
on an individual basis.    
4.2.2 The effect of antipsychotics on AEDs 
In general terms, both FGAP and SGAP do not seem to have major influence on enzymatic pathways 
leading to interactions with AEDs.   
4.3 Pharmacodynamic interactions between antiepileptic and antipsychotic drugs 
As already discussed for antidepressants, data on pharmacodynamic interactions is generally limited. 
Favourable pharmacodynamic interactions between SGAP and AEDs, especially VPA, comprise well 
known augmentation strategies for the treatment of mania (63,64). The combined prescription of 
TPM or zonisamide (ZNS) may represent another possible favourable pharmacodynamic interaction 
as both AEDs may reverse SGAP-induced weight gain (61,65). Negative pharmacodynamic 
interactions are not systematically studies. In general terms, those that can be considered clinically 
relevant include increased sedation, weight gain and hematologic problems. Additive sedation with 
antipsychotics seems to be relevant for all first generation AEDs and TPM. Additive weight gain is 
particularly evident for the combination of VPA and olanzapine (66) but it should be considered 
when olanzapine is combined with any AED associated with this side effect such as CBZ, gabapentin 
(GBP) and pregabalin (PGB) (67). CBZ-clozapine combination is not recommended due to the 
increased risk of agranulocytosis but it is recommended to be clinically vigilant for possible 
leukopenia when VPA is coprescribed with clozapine or olanzapine (61).  
4.4 Effect of antipsychotics on seizure threshold 
While the supposed proconvulsant effect of antidepressants is still matter of debate, this seems to 
be established for antipsychotics. However, it has to be acknowledge that this has been 
demonstrated mainly for clozapine while all other antipsychotics, especially SGAP, seem to have a 
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low proconvulsant risk (48). For clozapine the risk seems to be both titration- and dose-dependent. A 
US case series documented a mean prevalence of seizures during clozapine treatment of 2.9% with 
prevalence rates of 1%, 2.7% and 4.4% for dosages of <300 mg, 300-600 mg and >600 mg 
respectively (68). Prevalence rates are much lower in patients without a previous history of seizures 
(69) confirming that clozapine can deteriorate seizures in predisposed individuals. Up to 5% of 
patients treated with clozapine can have EEG abnormalities (70) but whether this is a predictive 
factor for clozapine-induced seizures is still unknown. In general terms, clozapine seems to 
deteriorate mainly myoclonic jerks but generalised tonic clonic seizures or even focal seizures have 
been reported in predisposed individuals (70). Chlorpromazine is another antipsychotic with an 
increased risk of seizures but this seems to be a major concern only for high doses (>1000 mg/day) 
which are rarely used in clinical practice (45). Apart from clozapine, SGAP seem to be generally safe 
in people with epilepsy but careful clinical monitoring is always advised.  
5. ATTENTION DEFICIT HYPERACTIVITY DISORDER  
5.1 Evidence from RCT in epilepsy 
Epidemiological studies consistently show that attention deficit hyperactivity disorder (ADHD) is 2 to 
3 times more common in people with epilepsy than in the general population (1,71). Demographic 
data shows an equal male-female ratio in epilepsy whereas males are more often affected in 
samples with isolated ADHD as seen in paediatric clinics (71). Despite the limited number of studies 
investigating ADHD subtypes in epilepsy, there seems to be more inattentive presentations in 
patients with epilepsy as compared to ADHD in psychiatric samples. 
Guidance of treatment of ADHD outside epilepsy recommends either methylphenidate or 
amphetamine, switching to the stimulant not previously used if the patient fails to respond or has 
side effects, and atomoxetine as second line agent if stimulants are not effective or cause adverse 
effects (72). In general terms, there is more data on methylphenidate than amphetamine in patients 
with epilepsy and ADHD. Three randomised, double-blind, placebo-controlled, cross-over trials 
showed that methylphenidate 0.3-1 mg/kg/day is effective and well tolerated in children with 
epilepsy and ADHD with response rates ranging between 60% and 70% (73–75). For amphetamine, 
there is just a retrospective study of 36 patients with epilepsy and ADHD that compared response 
rates of amphetamine and methylphenidate and showed a significant improvement in 63% of 
patients taking methylphenidate versus 24% of those on amphetamine (76).  
In case methylphenidate fails guidelines of treatment would recommend atomoxetine but data in 
patients with epilepsy are more than scant with just a retrospective study documenting up to 63% 
discontinuation rates mainly due to inefficacy (77). 
5.2 Pharmacokinetic interactions between antiepileptic drugs and psychostimulants 
Despite early reports about possible interactions between methylphenidate and first generation 
antiepileptic drugs (78,79), there is no data suggesting clinically relevant interactions with AEDs. In 
general terms, methylphenidate seems to have a moderate inhibitory effect on CYP enzymatic 
pathways (80) and for this reason clinical monitoring in individual cases is advisable. 
5.3 Effect of psychostimulants on seizure threshold 
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Historically, psychostimulants have represented the class of medications most frequently alleged to 
trigger seizures. However, especially for methylphenidate, clinical data from both RCT and open 
trials clearly suggests that this is not the case as no seizure worsening has been demonstrated in any 
single trial (73–75,81). Data on amphetamines are very limited (82).  
6. CONCLUSIONS 
Psychiatric disorders represent frequent comorbidities in patients with epilepsy affecting quality of 
life, morbidity and mortality (83). Evidence-based data on the management of these conditions are 
limited but a number of recommendations are now available to guide clinical practice. Careful 
clinical monitoring is always advisable and the “start low go slow” recommendation still represents 
the best practice bearing in mind that low starting doses do not necessarily mean low target doses. 
Continuous monitoring of quality of life of patients is always advisable (84) and full remissions 
from psychiatric symptoms should always be the ultimate goal as many studies demonstrated that 
subthreshold or residual symptoms still affect quality of life of patients with epilepsy (85).  
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Table 1. Classification of psychiatric symptoms according to their temporal relation with seizures. 
 
PERI-ICTAL 
PRE-ICTAL  
ICTAL (Focal seizures with psychic symptoms) 
POST-ICTAL 
INTER-ICTAL Unrelated to seizure occurrence 
 
 
 
Table 2. Spectrum of side effects and potential negative pharmacodynamic interactions. 
 Sedation  Weight gain Hyponatraemia  Arrhythmias  Sexual 
dysfunction 
Urinary 
retention 
Osteoporosis  Bleeding 
ADs  TCAs 
Trazodone  
Mirtazapine 
TCAs 
Mirtazapine 
Paroxetine  
SSRIs Citalopram 
Fluoxetine 
Sertraline 
Duloxetine 
Reboxetine 
Venlafaxine  
SSRIs 
TCAs 
 
TCAs 
Paroxetine 
Mirtazapine 
SSRIs SSRIs 
AEDs  All except  
Felbamate 
Lacosamide 
Lamotrigine 
Tiagabine  
Carbamazepine 
Valproate 
Gabapentin 
Pregabalin  
Retigabine  
 
Carbamazepine 
Oxcarbazepine 
Eslicarbazepine 
Felbamate 
Retigabine  
Carbamaze
pine 
Retigabine  Carbamazepine 
Barbiturates 
Phenytoin 
Valproate 
Topiramate 
 
Valproate 
ADs = antidepressant drugs; AEDs = antiepileptic drugs 
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Table 3. Risk factors for drug-related seizures. 
Patient-related History of epilepsy 
Family History of epilepsy 
Brain disorder (post-natal brain damage, head injury, dementia) 
Treatment-related  High-dose or overdose 
Rapid titration  
Abrupt withdrawal (i.e. benzodiazepines or antiepileptic drugs) 
Pharmacodynamic interactions (i.e. effect on seizure threshold) 
Pharmacokinetic interactions (i.e. inhibition -> overdose/high-dose) 
 
  
18 
 
Table 4. Prevalence of seizures with antidepressant drugs. 
 
 
  
 
  
DRUG DOSE 
REPORTED 
(%) 
EXPECTED 
(%) 
Amitriptyline 
<200 mg 
>200 mg 
0.1 
0.6 
0.25 
(95%CI 0.20-0.35) 
Imipramine 50-600 mg <0.1-0.9 
Clomipramine >200 mg 0.5 
Maprotiline 150-200 mg 0.4 
Fluoxetine 20-60 mg 0.2 
Fluvoxamine <100 mg 0.2 
Sertraline 50-100 mg <0.1 
Paroxetine 20-60 mg 0.1 
Bupropion 
300 mg SR 
300-450 mg IR 
>450mg IR 
0.1 
0.4 
>0.6 
Mirtazapine 30 mg <0.1 
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Table 5. Treatment of anxiety disorders in epilepsy. 
Panic attack disorder 1. SSRIs (any) + CBT or CBT alone 
Generalized anxiety disorder 1. Pregabalin 
2. Paroxetine, Venlafaxine, Imipramine 
Social anxiety disorder 1. SSRIs (sertraline, escitalopram, paroxetine) 
Post-traumatic stress disorder 1. SSRIs (sertraline, paroxetine) 
Obsessive-compulsive disorder 1. CBT 
2. CBT + sertraline 
3. CBT + clomipramine 
CBT = Cognitive behavioural therapy 
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Table 6. Classification of antipsychotic drugs. 
First Generation Antipsychotics 
Chlorpromazine  
Droperidol  
Fluphenazine  
Haloperidol   
Loxapine  
Perphenazine  
Pimozide  
Prochlorperazine  
Thiothixene  
Thioridazine  
Trifluoperazine 
Second Generation Antipsychotics 
Aripiprazole  
Asenapine   
Clozapine  
IIoperidone  
Olanzapine  
Paliperidone  
Quetiapine  
Risperidone  
Ziprasidone 
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Figure Legend 
Figure 1. Spectrum of activity of SSRIs on different receptors. 5HT = serotonin receptor; DRI = 
dopamine reuptake inhibition; SRI = serotonin reuptake inhibition; H = histamine receptors; NRI = 
noradrenaline reuptake inhibition; NOS = Nitric oxide synthesis; M = Muscarinic receptors; σ = 
opioid receptor  
Supplementary Material. Definition and criteria for side effects and their relevance for seizures as 
a side effect of antidepressants.   
 
 
 
 
 
